title: Comparison of the long-term results of brachytherapy for T1-2N0 oral tongue cancer treated with Ir-192 and Ra-226.
abstract: BACKGROUND
  The authors report the compatibility of iridium-192 (Ir-192) to Radium-226 (Ra-226) based on the clinical results of three-decades.
  
  
  METHODS
  From 1967 through 1985, 119 patients with early oral tongue cancer (T1-2N0) were treated with conventional Ra-226 needles and 135 patients with Ir-192 hair pins.
  
  
  RESULTS
  Local control rates at 10 years for T1 and T2 tongue cancer were 79% and 61% for patients treated with Ra-226, 83% and 68% with Ir-192. The 10-year cause-specific survival rates for the T1 and T2 patients with Ra-226 were 76% and 63%, and those with Ir-192 were 77% and 68%, respectively.
  
  
  CONCLUSIONS
  Ir-192 showed good possibilities as a substitute for Ra-226 in brachytherapy for early oral tongue cancer.
authors.affiliation: Department of Radiation Oncology, Osaka University Medical School, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Yamazaki
authors.forename: T
authors.initials: T
authors.lastname: Inoue
authors.forename: M
authors.initials: M
authors.lastname: Koizumi
authors.forename: K
authors.initials: K
authors.lastname: Yoshida
authors.forename: K
authors.initials: K
authors.lastname: Kagawa
authors.forename: H
authors.initials: H
authors.lastname: Shiomi
authors.forename: T
authors.initials: T
authors.lastname: Nose
authors.forename: E
authors.initials: E
authors.lastname: Tanaka
authors.forename: T
authors.initials: T
authors.lastname: Teshima
authors.forename: H
authors.initials: H
authors.lastname: Nakamura
authors.forename: K
authors.initials: K
authors.lastname: Shimizutani
authors.forename: S
authors.initials: S
authors.lastname: Furukawa
authors.forename: H
authors.initials: H
authors.lastname: Fuchihata
authors.forename: T
authors.initials: T
authors.lastname: Inoue
mesh_terms: D000328:Adult; D000368:Aged; D001918:Brachytherapy; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007496:Iridium Radioisotopes / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011883:Radium / Q000627:therapeutic use*; D016019:Survival Analysis; D014062:Tongue Neoplasms / Q000532:radiotherapy*
chemical_list: D007496:Iridium Radioisotopes; D011883:Radium